Boston Scientific's ACURATE Prime Aortic Valve System Wins CE Mark

Core Insights - Boston Scientific has received a CE Mark for the ACURATE Prime Aortic Valve System, enhancing its transcatheter aortic valve replacement (TAVR) technology portfolio [1][2][3] - The new valve system is designed for patients with severe aortic stenosis and offers improved deployment mechanisms and performance in complex cases [2][3] - The global TAVR market is valued at $6.3 billion in 2023, with a projected CAGR of 7.2% by 2030, driven by factors such as the rising prevalence of aortic valve stenosis and the demand for minimally invasive procedures [4] Company Developments - Boston Scientific's second-quarter 2024 financial report indicated strong organic growth in its Cardiology business, particularly in Interventional Cardiology Therapies and Structural Heart Valves [5] - The company plans to launch the ACURATE Prime system in Europe soon, while it remains investigational in the United States [3] - The ACURATE valve platform has been implanted in nearly 80,000 patients globally, showcasing its clinical adoption [3] Market Performance - BSX shares have increased by 46.5% over the past year, outperforming the industry average of 12.7% [7] - Earnings estimates for Boston Scientific's 2024 remain constant at$ 2.40, with the company consistently beating estimates in the past four quarters [8] - Boston Scientific currently holds a Zacks Rank 2 (Buy), indicating positive market sentiment [9]